Chronic graft-versus-host disease (cGVHD) is a major cause of late mortality following allogeneic bone marrow transplantation (BMT) and is characterized by tissue fibrosis manifesting as scleroderma and bronchiolitis obliterans. The development of acute GVHD (aGVHD) is a powerful clinical predictor of subsequent cGVHD, suggesting that aGVHD may invoke the immunologic pathways responsible for cGVHD. In preclinical models in which sclerodermatous cGVHD develops after a preceding period of mild aGVHD, we show that antigen presentation within major histocompatibility complex (MHC) class II of donor dendritic cells (DCs) is markedly impaired early after BMT. This is associated with a failure of regulatory T-cell (Treg) homeostasis and cGVHD. Don...
Acute graft-versus-host disease (aGvHD) is a frequent complication after allogeneic bone marrow/stem...
Chronic graft-versus-host disease (cGVHD) is a complication after minor antigen mismatched bone marr...
Acute graft versus host disease (aGVHD) affects more than 40% of patients undergoing haematopoietic ...
Chronic graft-versus-host disease (cGVHD) is a major cause of late mortality following allogeneic bo...
Alloreactivity after transplantation is associated with profound immune suppression, and consequent ...
Alloreactivity after transplantation is associated with profound immune suppression, and consequent ...
Viral infection is a common, life-threatening complication after allogeneic bone marrow transplantat...
AbstractGraft-versus-host disease (GVHD) causes significant morbidity and mortality in patients unde...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
The role of Ag presenting cell subsets in graft-versus-host disease (GVHD) remains unclear. We have ...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subs...
Acute graft-versus-host disease (aGvHD) is a frequent complication after allogeneic bone marrow/stem...
Chronic graft-versus-host disease (cGVHD) is a complication after minor antigen mismatched bone marr...
Acute graft versus host disease (aGVHD) affects more than 40% of patients undergoing haematopoietic ...
Chronic graft-versus-host disease (cGVHD) is a major cause of late mortality following allogeneic bo...
Alloreactivity after transplantation is associated with profound immune suppression, and consequent ...
Alloreactivity after transplantation is associated with profound immune suppression, and consequent ...
Viral infection is a common, life-threatening complication after allogeneic bone marrow transplantat...
AbstractGraft-versus-host disease (GVHD) causes significant morbidity and mortality in patients unde...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans...
The role of Ag presenting cell subsets in graft-versus-host disease (GVHD) remains unclear. We have ...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subs...
Acute graft-versus-host disease (aGvHD) is a frequent complication after allogeneic bone marrow/stem...
Chronic graft-versus-host disease (cGVHD) is a complication after minor antigen mismatched bone marr...
Acute graft versus host disease (aGVHD) affects more than 40% of patients undergoing haematopoietic ...